Income statement
USD
Annual
| Metric | 2025 |
|---|---|
| Revenue | 19M |
| Gross Profit | 19M |
| Operating Income | -77M |
| EBITDA | -76M |
| Net Income | -77M |
| EPS (Diluted) | — |
Healthcare
Live Price
Offline$12.66
+1.44% today
1Y Change
-56.74%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Atrium Therapeutics, Inc. (RNA) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $12.66 and down 56.7% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin -412.6% and ROIC -31.9%. Valuation already assumes a fairly strong business story at price/sales 11.2. Stock Foundry combines RNA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RNA Max Drawdown
-84.16%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RNA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$18.6M
FY Net Income
-$76.7M
Free Cash Flow
-$42.6M
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
100.0%
Net Margin
-411.9%
Income statement
USD
| Metric | 2025 |
|---|---|
| Revenue | 19M |
| Gross Profit | 19M |
| Operating Income | -77M |
| EBITDA | -76M |
| Net Income | -77M |
| EPS (Diluted) | — |
Balance sheet
USD
| Metric | 2025 |
|---|---|
| Cash & Equivalents | 270M |
| Total Assets | 278M |
| Total Liabilities | 71M |
| Shareholder Equity | 207M |
| Total Debt | 4M |
| Net Debt | -266M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
41M
Capital Expenditures
1M
Free Cash Flow
43M
Key ratios
Gross Margin
100.0%
Operating Margin
-412.6%
Net Margin
-411.9%
ROE
-37.0%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.